AmpliPhi Biosciences (NYSEAMERICAN:APHB) has been given a $6.00 price objective by research analysts at HC Wainwright in a report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 282.17% from the company’s previous close.
AmpliPhi Biosciences (NYSEAMERICAN:APHB) opened at $1.57 on Thursday. The firm has a market capitalization of $21.87, a PE ratio of -0.15 and a beta of 2.76. AmpliPhi Biosciences has a one year low of $0.67 and a one year high of $5.20.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/17/ampliphi-biosciences-aphb-given-a-6-00-price-target-by-hc-wainwright-analysts.html.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for AmpliPhi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmpliPhi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.